Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1988-03-31
1993-02-09
Wax, Robert A.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 21, 424 851, C07K 1506
Patent
active
051853230
ABSTRACT:
Antimaturation factor (platelet factor 4 or active peptide segments thereof) is employed in the clinical treatment of coagulation disorders as an anticoagulant operating via an autoregulator mechanism for selectively suppressing megakaryocytopoiesis. Exposure of immature megakaryocytes to antimaturation factor reversibly inhibits cell maturation and, accordingly, functions characteristic of the mature cell, including platelet production and expression of genes coding for platelet coagulation factors, are reversibly suppressed.
REFERENCES:
patent: 4702908 (1987-10-01), Thorbecke et al.
A. Gewirtz, W. Y. Xu, B. Rueinski, and S. Niewiarowski, Highly Purified Platelet Factor 4 Selectively Inhibits In Vitro Human Megacaryorytopoiesis, Clinical Research, vol. 35, No. 3. Apr. 1987.
A. Gewirtz, B. Callabretta, B. Rucinski, and S. Niewiarowski, Studies on the Mechanism of Platelet Factor 4 Induced Inhibition of Human Megacaryocytopoiesis in Vitro; Blood, vol. 70 (Supplement #1), p. 153a, Nov. 1990.
Gewirtz et al. Jul. 6-10, 1987, Thromb. Haemostasis 58(1):493, Abstract No. 1822.
Furman Keith C.
Temple University
Wax Robert A.
LandOfFree
Suppression of megakaryocytopoiesis employing platelet factor 4 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Suppression of megakaryocytopoiesis employing platelet factor 4 , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Suppression of megakaryocytopoiesis employing platelet factor 4 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-325639